Impact of #FGFR Inhibitors in #bladdercancer #cancer #uc #news #cancerresearch
Monika Joshi, MD, MRCP, of Penn State Cancer Institute, contextualizes the results of the THOR study within the treatment landscape for FGFR2/3-altered advan…
Monika Joshi, MD, MRCP, of Penn State Cancer Institute, contextualizes the results of the THOR study within the treatment landscape for FGFR2/3-altered advan…
This cohort study examines the applicability of personalized colorectal cancer (CRC) screening with fecal-hemoglobin (f-Hb)-guided screening intervals to reduce the number of fecal immunological tests…
Lucy Bujnoch and her two kids, Mike Gonzalez and Rebecca Bujnoch, each have a different role at MD Anderson but work in the same department.
First-line treatment with the combination of Versamune HPV and pembrolizumab met a best overall response end point in recurrent/metastatic HNSCC.
Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for…
OCE experts regularly join colleagues to participate in major conferences.
Here, we summarize a meta-analysis by Soltantabar et al. published in Clinical Pharmacology and Therapeutics on the impact of treatment modality and the route of…
🎬🌟 Season 2 Kickoff: “All Things Lifts” in the Hope & Housing ALS SeriesExciting news! We’re launching Season 2 of our transformative Hope & Housing…
This survey is intended to better understand your membership experience at IASLC as it relates to diversity, equity, inclusion, and accessibility. We want to explore…
Cryo-EM structure of the type I antiphospholipid antibody POmAb bound to the region R90-Y93 of kringle-1 of prothrombin is described.By forcing prothrombin
During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the…